These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 38048563)

  • 1. Intraoperative Radioguided Localization of an Occult Neuroendocrine Tumor of the Ileum.
    Manca G; Nonne G; Volterrani D
    Clin Nucl Med; 2024 Jan; 49(1):69-70. PubMed ID: 38048563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intraoperative somatostatin receptor detection after peptide receptor radionuclide therapy with (177)Lu- and (90)Y-DOTATOC (tandem PRRNT) in a patient with a metastatic neuroendocrine tumor.
    Todorović-Tirnanić M; Kaemmerer D; Prasad V; Hommann M; Baum RP
    Recent Results Cancer Res; 2013; 194():487-96. PubMed ID: 22918778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimizing Somatostatin Receptor Imaging in Patients With Neuroendocrine Tumors: The Impact of 99mTc-HYNICTOC SPECT/SPECT/CT Versus 68Ga-DOTATATE PET/CT Upon Clinical Management.
    Kunikowska J; Lewington V; Krolicki L
    Clin Nucl Med; 2017 Dec; 42(12):905-911. PubMed ID: 29076910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intraoperative gamma probe detection of neuroendocrine tumors.
    Adams S; Baum RP; Hertel A; Wenisch HJ; Staib-Sebler E; Herrmann G; Encke A; Hör G
    J Nucl Med; 1998 Jul; 39(7):1155-60. PubMed ID: 9669386
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Localization of Unknown Primary Site with
    Menda Y; O'Dorisio TM; Howe JR; Schultz M; Dillon JS; Dick D; Watkins GL; Ginader T; Bushnell DL; Sunderland JJ; Zamba GKD; Graham M; O'Dorisio MS
    J Nucl Med; 2017 Jul; 58(7):1054-1057. PubMed ID: 28153957
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hybrid radioguided occult lesion localization (hybrid ROLL) of (18)F-FDG-avid lesions using the hybrid tracer indocyanine green-(99m)Tc-nanocolloid.
    KleinJan GH; Brouwer OR; Mathéron HM; Rietbergen DD; Valdés Olmos RA; Wouters MW; van den Berg NS; van Leeuwen FW
    Rev Esp Med Nucl Imagen Mol; 2016; 35(5):292-7. PubMed ID: 27174865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radioguided detection of a non-palpable occult lesion (ROLL) in a case of abdominal metastasis of a neuroendocrine tumor.
    Badenes Romero Á; Orozco Cortés J; Balaguer Muñoz D; Abreu Sánchez P; Mut Dólera T; Gómez Abril SÁ; Dolz Gaitón R; Caballero Calabuig E; Cueto Cañadas B; Latorre Agraz I; Reyes Ojeda MD; Plancha Mansanet C; Esteban Hurtado Á
    Rev Esp Enferm Dig; 2020 Oct; 112(10):768-771. PubMed ID: 33023293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imaging of Chemokine Receptor 4 Expression in Neuroendocrine Tumors - a Triple Tracer Comparative Approach.
    Werner RA; Weich A; Higuchi T; Schmid JS; Schirbel A; Lassmann M; Wild V; Rudelius M; Kudlich T; Herrmann K; Scheurlen M; Buck AK; Kropf S; Wester HJ; Lapa C
    Theranostics; 2017; 7(6):1489-1498. PubMed ID: 28529632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of a well-differentiated pancreatic neuroendocrine tumor with
    Prado-Wohlwend S; Ballesta-Moratalla M; Torres-Espallardo I; Del Olmo-García MI; Sánchez-Vañó R; Bello-Arques P
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2021; 40(4):259-260. PubMed ID: 34218892
    [No Abstract]   [Full Text] [Related]  

  • 11. Head-to-Head Comparison of
    Johnbeck CB; Knigge U; Loft A; Berthelsen AK; Mortensen J; Oturai P; Langer SW; Elema DR; Kjaer A
    J Nucl Med; 2017 Mar; 58(3):451-457. PubMed ID: 27660147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Time Evolution of DOTATOC Uptake in Neuroendocrine Tumors in View of a Possible Application of Radioguided Surgery with β- Decay.
    Collamati F; Bellini F; Bocci V; De Lucia E; Ferri V; Fioroni F; Grassi E; Iori M; Marafini M; Morganti S; Paramatti R; Patera V; Recchia L; Russomando A; Sarti A; Sciubba A; Senzacqua M; Solfaroli Camillocci E; Versari A; Voena C; Faccini R
    J Nucl Med; 2015 Oct; 56(10):1501-6. PubMed ID: 26338895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of 68Ga-DOTATOC positron emission tomography/computed tomography on the multimodal management of patients with neuroendocrine tumors.
    Frilling A; Sotiropoulos GC; Radtke A; Malago M; Bockisch A; Kuehl H; Li J; Broelsch CE
    Ann Surg; 2010 Nov; 252(5):850-6. PubMed ID: 21037441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential role of (68)Ga-DOTATOC PET/CT in screening for pancreatic neuroendocrine tumour in patients with von Hippel-Lindau disease.
    Prasad V; Tiling N; Denecke T; Brenner W; Plöckinger U
    Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):2014-20. PubMed ID: 27293206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 68Ga-DOTATATE PET/CT, 99mTc-HYNIC-octreotide SPECT/CT, and whole-body MR imaging in detection of neuroendocrine tumors: a prospective trial.
    Etchebehere EC; de Oliveira Santos A; Gumz B; Vicente A; Hoff PG; Corradi G; Ichiki WA; de Almeida Filho JG; Cantoni S; Camargo EE; Costa FP
    J Nucl Med; 2014 Oct; 55(10):1598-604. PubMed ID: 25168627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Additional information gained by positron emission tomography with (68)Ga-DOTATOC for suspected unknown primary or recurrent neuroendocrine tumors.
    Nakamoto Y; Sano K; Ishimori T; Ueda M; Temma T; Saji H; Togashi K
    Ann Nucl Med; 2015 Jul; 29(6):512-8. PubMed ID: 25894056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Within-patient comparison between [
    Mahieu R; Donders DNV; Krijger GC; Ververs FFT; de Roos R; Bemelmans JLMM; van Rooij R; de Bree R; de Keizer B
    Eur J Nucl Med Mol Imaging; 2022 May; 49(6):2023-2036. PubMed ID: 34962582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ⁶⁸Ga-DOTANOC PET/CT in patients with carcinoma of unknown primary of neuroendocrine origin.
    Naswa N; Sharma P; Kumar A; Soundararajan R; Kumar R; Malhotra A; Ammini AC; Bal C
    Clin Nucl Med; 2012 Mar; 37(3):245-51. PubMed ID: 22310250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First
    Bertani E; Collamati F; Colandrea M; Faccini R; Fazio N; Ferrari ME; Fischetti M; Fumagalli Romario U; Funicelli L; De Simoni M; Mancini-Terracciano C; Mirabelli R; Morganti S; Papi S; Pisa E; Solfaroli-Camillocci E; Spada F; Cremonesi M; Grana CM
    Cancer Biother Radiopharm; 2021 Jun; 36(5):397-406. PubMed ID: 33601932
    [No Abstract]   [Full Text] [Related]  

  • 20. 68 Ga-DOTATOC PET/CT in Pancreatic Metastasis From Clear Cell Renal Cell Carcinoma.
    Mansour N; Rangan K; Tiling R; Rübenthaler J; Fabritius MP
    Clin Nucl Med; 2023 Aug; 48(8):712-713. PubMed ID: 37276508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.